大砍研发费用的君实生物仍在创新药盈利俱乐部门外

界面
28 Mar

界面新闻记者 |李科文界面新闻编辑 |谢欣君实生物扔在冲击创新药盈利俱乐部。3月28日,君实生物公布2024年年报。2024年,君实生物实现营收19.48亿元,同比增长29.67%。亏损继续收窄,但仍未能扭亏为盈,为亏损12.8亿元。因进医保而持续放量的首个国产PD-1单抗特瑞普利单抗并没能帮助君实生物扭亏为盈。虽然净亏损继续收窄,很大程度仍依赖于削减研发支出。据君实生物年报,2024年公司研发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10